If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

In vitro and in vivo characterization and strain safety of Lactobacillus reuteri NCIMB 30253 for probiotic applications

$50.00 plus tax (Refund Policy)

Buy Article:

Abstract:

Lactobacillus reuteri NCIMB 30253 was shown to have potential as a probiotic by reducing the proinflammatory chemokine interleukin-8. Moreover, this strain was evaluated, by in vitro and in vivo techniques, for its safety for human consumption. The identity of the strain was investigated by metabolic profiling and 16S rRNA gene sequencing, and in vitro safety evaluations were performed by molecular and metabolic techniques. Genetic analysis was confirmed by assessing the minimum inhibitory concentration to a panel of antibiotics, showing that the strain was susceptible to 8 antibiotics tested. The ability of the strain to produce potentially harmful by-products and antimicrobial compounds was evaluated, showing that the strain does not produce biogenic amines and does not show bacteriocin activity or reuterin production. A 28-day repeated oral dose study was conducted in normal Sprague–Dawley rats to support the in vivo strain safety. Oral administration of the strain resulted in no changes in general condition and no clinically significant changes to biochemical and haematological markers of safety relative to vehicle control treated animals. This comprehensive assessment of safety of L. reuteri NCIMB 30253 supports the safety of the strain for use as a probiotic.

Keywords: Lactobacillus reuteri; bacteria; bactérie; health food probiotics; innocuité de la souche; probiotics; probiotiques; probiotiques alimentaires pour la santé; strain safety

Document Type: Research Article

DOI: http://dx.doi.org/10.1139/w2012-050

Affiliations: 1: Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, Physiology and Artificial Cells and Organs Research Centre, Faculty of Medicine, McGill University, 3775 University Street, Montréal, QC H3A 2B4, Canada. 2: Micropharma Limited, 141 avenue du President Kennedy, Université du Québec a Montréal, Biological Sciences Building, 5th Floor, Suite 5569, Montréal, QC H2X 3Y7, Canada. 3: Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, Physiology and Artificial Cells and Organs Research Centre, Faculty of Medicine, McGill University, 3775 University Street, Montréal, QC H3A 2B4, Canada.

Publication date: June 22, 2012

More about this publication?
  • Published since 1954, this monthly journal contains new research in the field of microbiology including applied microbiology and biotechnology; microbial structure and function; fungi and other eucaryotic protists; infection and immunity; microbial ecology; physiology, metabolism and enzymology; and virology, genetics, and molecular biology. It also publishes review articles and notes on an occasional basis, contributed by recognized scientists worldwide.
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Terms & Conditions
  • Sample Issue
  • Reprints & Permissions
  • ingentaconnect is not responsible for the content or availability of external websites
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more